Ta Viet Hung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ta Viet Hung has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Bui Chi Thuong
University of Medicine and Pharmacy Ho Chi Minh City Vietnam
1 shared publication - Pham Dinh Nguyen
University of Medicine and Pharmacy Ho Chi Minh City Vietnam
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Risk Stratification and Safety Profile of Pharmacological Prophylaxis for Venous Thromboembolism in Postpartum Women Following Cesarean Section: A Comparative Evaluation
Objective: Venous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality worldwide. This study evaluated VTE risk stratification among postpartum women following cesarean section, compared the 2023 National Guidelines (NG) with the Caprini score, and assessed pharmacological thromboprophylaxis safety. Methods: A single-center prospective cohort study was conducted on 386 women undergoing cesarean delivery at Nhan Dan Gia Dinh Hospital between February and July 2025. VTE risk was independently assessed using the 2023 NG and Caprini score. Demographic characteristics, operative variables, and short-term inpatient outcomes related to low-molecular-weight heparin (LMWH) or unfractionated heparin prophylaxis were analyzed. Results: According to the 2023 NG, 71.0% of patients were classified as low risk, 15.5% as intermediate risk, and 13.5% as high risk. Major risk factors included emergency cesarean delivery (45.3%), maternal age above 35 years (23.1%), and obesity (20.5%). Using the Caprini score, 45.3% met criteria for pharmacological prophylaxis, representing a 56.2% increase compared with the 2023 NG. Among 110 women receiving thromboprophylaxis, LMWH accounted for 99.1% of treatment. No severe hemorrhagic complications or thrombocytopenia were observed. Adverse events were mild and localized, mainly injection-site ecchymosis. Conclusion: The 2023 NG generated fewer pharmacological prophylaxis indications than the Caprini score in this cohort. LMWH prophylaxis showed favorable short-term inpatient safety after cesarean delivery. Because follow-up was limited to hospitalization and the study was not powered for rare VTE events, these findings should be interpreted as allocation patterns and short-term safety rather than comparative effectiveness.
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessRisk Stratification and Safety Profile of Pharmacological Prophylaxis for Venous Thromboembolism in Postpartum Women Following Cesarean Section: A Comparative Evaluation
Objective: Venous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality worldwide. This study evaluated VTE risk stratification among postpartum women following cesarean section, compared the 2023 National Guidelines (NG) with the Caprini score, and assessed pharmacological thromboprophylaxis safety. Methods: A single-center prospective cohort study was conducted on 386 women undergoing cesarean delivery at Nhan Dan Gia Dinh Hospital between February and July 2025. VTE risk was independently assessed using the 2023 NG and Caprini score. Demographic characteristics, operative variables, and short-term inpatient outcomes related to low-molecular-weight heparin (LMWH) or unfractionated heparin prophylaxis were analyzed. Results: According to the 2023 NG, 71.0% of patients were classified as low risk, 15.5% as intermediate risk, and 13.5% as high risk. Major risk factors included emergency cesarean delivery (45.3%), maternal age above 35 years (23.1%), and obesity (20.5%). Using the Caprini score, 45.3% met criteria for pharmacological prophylaxis, representing a 56.2% increase compared with the 2023 NG. Among 110 women receiving thromboprophylaxis, LMWH accounted for 99.1% of treatment. No severe hemorrhagic complications or thrombocytopenia were observed. Adverse events were mild and localized, mainly injection-site ecchymosis. Conclusion: The 2023 NG generated fewer pharmacological prophylaxis indications than the Caprini score in this cohort. LMWH prophylaxis showed favorable short-term inpatient safety after cesarean delivery. Because follow-up was limited to hospitalization and the study was not powered for rare VTE events, these findings should be interpreted as allocation patterns and short-term safety rather than comparative effectiveness.